We propose that future studies into TIMP2 activity in the TME may reveal potential avenues for the use of TIMP2, or similar biological agents, as a cancer biotherapeutic that may offer viable treatment options in combination with other directed anti-tumor therapies. This evidence concerns the gene TIMP2 and neoplasm.